Literature DB >> 19619138

Age-dependent dysregulation of brain amyloid precursor protein in the Ts65Dn Down syndrome mouse model.

Jennifer H K Choi1, Jason D Berger, Matthew J Mazzella, Jose Morales-Corraliza, Anne M Cataldo, Ralph A Nixon, Stephen D Ginsberg, Efrat Levy, Paul M Mathews.   

Abstract

Individuals with Down syndrome develop beta-amyloid deposition characteristic of early-onset Alzheimer's disease (AD) in mid-life, presumably because of an extra copy of the chromosome 21-located amyloid precursor protein (App) gene. App mRNA and APP metabolite levels were assessed in the brains of Ts65Dn mice, a mouse model of Down syndrome, using quantitative PCR, western blot analysis, immunoprecipitation, and ELISAs. In spite of the additional App gene copy, App mRNA, APP holoprotein, and all APP metabolite levels in the brains of 4-month-old trisomic mice were not increased compared with the levels seen in diploid littermate controls. However starting at 10 months of age, brain APP levels were increased proportional to the App gene dosage imbalance reflecting increased App message levels in Ts65Dn mice. Similar to APP levels, soluble amino-terminal fragments of APP (sAPPalpha and sAPPbeta) were increased in Ts65Dn mice compared with diploid mice at 12 months but not at 4 months of age. Brain levels of both Abeta40 and Abeta42 were not increased in Ts65Dn mice compared with diploid mice at all ages examined. Therefore, multiple mechanisms contribute to the regulation towards diploid levels of APP metabolites in the Ts65Dn mouse brain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19619138      PMCID: PMC2744432          DOI: 10.1111/j.1471-4159.2009.06277.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  51 in total

1.  An analysis of the morphology of senile plaques in Down's syndrome patients of different ages using immunocytochemical and lectin histochemical techniques.

Authors:  D M Mann; A Brown; D Prinja; C A Davies; M Landon; C L Masters; K Beyreuthers
Journal:  Neuropathol Appl Neurobiol       Date:  1989 Jul-Aug       Impact factor: 8.090

2.  Normal brain development in PS1 hypomorphic mice with markedly reduced gamma-secretase cleavage of betaAPP.

Authors:  R Rozmahel; J Huang; F Chen; Y Liang; V Nguyen; M Ikeda; G Levesque; G Yu; M Nishimura; P Mathews; S D Schmidt; M Mercken; C Bergeron; D Westaway; P St George-Hyslop
Journal:  Neurobiol Aging       Date:  2002 Mar-Apr       Impact factor: 4.673

3.  Retrograde amnesia produced by several treatments: evidence for a common neurobiological mechanism.

Authors:  P E Gold; D B Sternberg
Journal:  Science       Date:  1978-07-28       Impact factor: 47.728

4.  Amyloid precursor protein potentiates the neurotrophic activity of NGF.

Authors:  W C Wallace; C A Akar; W E Lyons
Journal:  Brain Res Mol Brain Res       Date:  1997-12-15

5.  Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome.

Authors:  D M Holtzman; D Santucci; J Kilbridge; J Chua-Couzens; D J Fontana; S E Daniels; R M Johnson; K Chen; Y Sun; E Carlson; E Alleva; C J Epstein; W C Mobley
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

6.  Impaired spatial working and reference memory in segmental trisomy (Ts65Dn) mice.

Authors:  G E Demas; R J Nelson; B K Krueger; P J Yarowsky
Journal:  Behav Brain Res       Date:  1998-02       Impact factor: 3.332

7.  Gene expression profiling in the adult Down syndrome brain.

Authors:  H E Lockstone; L W Harris; J E Swatton; M T Wayland; A J Holland; S Bahn
Journal:  Genomics       Date:  2007-10-22       Impact factor: 5.736

8.  A mouse model for Down syndrome exhibits learning and behaviour deficits.

Authors:  R H Reeves; N G Irving; T H Moran; A Wohn; C Kitt; S S Sisodia; C Schmidt; R T Bronson; M T Davisson
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

9.  Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation.

Authors:  W Q Qiu; D M Walsh; Z Ye; K Vekrellis; J Zhang; M B Podlisny; M R Rosner; A Safavi; L B Hersh; D J Selkoe
Journal:  J Biol Chem       Date:  1998-12-04       Impact factor: 5.157

10.  Transcript level alterations reflect gene dosage effects across multiple tissues in a mouse model of down syndrome.

Authors:  Pascal Kahlem; Marc Sultan; Ralf Herwig; Matthias Steinfath; Daniela Balzereit; Barbara Eppens; Nidhi G Saran; Mathew T Pletcher; Sarah T South; Gail Stetten; Hans Lehrach; Roger H Reeves; Marie-Laure Yaspo
Journal:  Genome Res       Date:  2004-07       Impact factor: 9.043

View more
  34 in total

1.  Neuroinflammatory Cytokines-The Common Thread in Alzheimer's Pathogenesis.

Authors:  W Sue T Griffin; Steven W Barger
Journal:  US Neurol       Date:  2010

Review 2.  Prospects for improving brain function in individuals with Down syndrome.

Authors:  Alberto C S Costa; Jonah J Scott-McKean
Journal:  CNS Drugs       Date:  2013-09       Impact factor: 5.749

Review 3.  mTOR in Down syndrome: Role in Aß and tau neuropathology and transition to Alzheimer disease-like dementia.

Authors:  Fabio Di Domenico; Antonella Tramutola; Cesira Foppoli; Elizabeth Head; Marzia Perluigi; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2017-08-12       Impact factor: 7.376

4.  Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes.

Authors:  Megan Stringer; Irushi Abeysekera; Jared Thomas; Jonathan LaCombe; Kailey Stancombe; Robert J Stewart; Karl J Dria; Joseph M Wallace; Charles R Goodlett; Randall J Roper
Journal:  Physiol Behav       Date:  2017-05-03

5.  Down syndrome and dementia: seizures and cognitive decline.

Authors:  Ira T Lott; Eric Doran; Vinh Q Nguyen; Anne Tournay; Nina Movsesyan; Daniel L Gillen
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

6.  Maternal Choline Supplementation Alters Basal Forebrain Cholinergic Neuron Gene Expression in the Ts65Dn Mouse Model of Down Syndrome.

Authors:  Christy M Kelley; Stephen D Ginsberg; Melissa J Alldred; Barbara J Strupp; Elliott J Mufson
Journal:  Dev Neurobiol       Date:  2019-06-09       Impact factor: 3.964

7.  Seeding plaques in Alzheimer's disease.

Authors:  Marco A M Prado; Gerald Baron
Journal:  J Neurochem       Date:  2012-03       Impact factor: 5.372

Review 8.  Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome.

Authors:  Eric D Hamlett; Heather A Boger; Aurélie Ledreux; Christy M Kelley; Elliott J Mufson; Maria F Falangola; David N Guilfoyle; Ralph A Nixon; David Patterson; Nathan Duval; Ann-Charlotte E Granholm
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

9.  Early endosomal abnormalities and cholinergic neuron degeneration in amyloid-β protein precursor transgenic mice.

Authors:  Jennifer H K Choi; Gurjinder Kaur; Matthew J Mazzella; Jose Morales-Corraliza; Efrat Levy; Paul M Mathews
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

10.  Lowering beta-amyloid levels rescues learning and memory in a Down syndrome mouse model.

Authors:  William J Netzer; Craig Powell; Yi Nong; Jacqueline Blundell; Lili Wong; Karen Duff; Marc Flajolet; Paul Greengard
Journal:  PLoS One       Date:  2010-06-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.